The dark side of dopaminergic therapies in Parkinson’s disease: shedding light on aberrant salience

CNS Spectrums ◽  
2017 ◽  
Vol 23 (6) ◽  
pp. 347-351
Author(s):  
Michele Poletti
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
Empirical Investigation ◽  
Dark Side ◽  
Dopaminergic Drugs ◽  
Psychosis Proneness ◽  
Attribute Salience ◽  
Aberrant Salience ◽  
Speculative Hypothesis

Psychotic subjects and patients with Parkinson’s disease (PD) “on” dopaminergic drugs, especially on dopamine agonists, present a hyperdopaminergic state that interferes with learning processing. These clinical populations present with distinct alterations of learning that share an increased potential motivational significance of stimuli: psychotic subjects may attribute salience to neutral stimuli, while medicated PD patients may overvalue rewards. Herein is discussed the speculative hypothesis that the hyperdopaminergic state induced by dopaminergic treatments, especially with dopamine agonists, may also facilitate the attribution of salience to neutral stimuli in PD patients, altering the physiological attribution of salience. Preliminary empirical evidence is in agreement with this speculative hypothesis, which needs further empirical investigation. The clinical implications of this hypothesis are discussed in relation to behavioral addictions, psychosis proneness, and enhanced creativity in medicated PD patients.

scholarly journals The Effect of Dopamine Agonists on Adaptive and Aberrant Salience in Parkinson's Disease

2011 ◽  
Vol 37 (4) ◽  
pp. 950-958 ◽  
Author(s):  
Helga Nagy ◽  
Einat Levy-Gigi ◽  
Zsuzsanna Somlai ◽  
Annamária Takáts ◽  
Dániel Bereczki ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
Aberrant Salience

A Review of Voltammetric Methods for Determination of Dopamine Agonists

2020 ◽  
Vol 16 ◽  
Author(s):  
Fatma Ağin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Biological Samples ◽  
Dopamine Agonists ◽  
Modified Electrodes ◽  
Nerve Cells ◽  
Electroanalytical Methods ◽  
Voltammetry Methods ◽  
Voltammetric Methods

Background: Dopamine agonists are useful drugs for the management of patients with Parkinson's disease in the early stages and in later stages of the disease. Parkinson's disease is a progressive neurodegenerative disease that primarily affects dopamine-producing nerve cells in the brain. They bind to dopamine receptors in nerve cells that regulate body movement and motor function. Electroanalytical methods are used in medicinal, clinical and pharmaceutical research. The voltammetry is one of the most commonly used electroanalytical methods. The aims of this review are to gather and discuss studies of voltammetric methods used in determination of dopamine agonists. Method: This review includes the use of various voltammetric methods for determination studies of dopamine agonists from pharmaceutical dosage forms and biological samples. These studies were examined in terms of used voltammetric method or methods, working electrode, buffer, pH and validation parameters. Results: Cabergoline, pramipexole, ropinirole have more studies, while bromocriptine and apomorphine have fewer studies in the literature. Differential pulse voltammetry and square wave voltammetry methods were the most applied methods for determination of dopamine agonist drugs from pharmaceuticals and biological samples. But, stripping, cyclic and lineer sweep voltammetry methods are less applied methods. In this studies, a lot of modified electrodes were developed and used to analyse of dopamine agonists. Conclusion: The voltammetric methods supply determination of therapeutic agents and/or their metabolites in clinical samples at extremely low concentrations without the necessity for the sample pre-treatment or time consuming extraction steps. Also the modified electrodes and validated voltammetric methods provide good stability, repeatability, reproducibility and high recovery for the analysis of the analyte.

Schizophrenia, Parkinson’s disease, and attention deficit hyperactivity disorder

2018 ◽  
Author(s):  
Richard J. Beninger
Keyword(s):  
Parkinson’S Disease ◽  
Attention Deficit Hyperactivity Disorder ◽  
Parkinson's Disease ◽  
Attention Deficit ◽  
Antipsychotic Treatment ◽  
Incentive Learning ◽  
Dopaminergic Drugs ◽  
Dopaminergic Neurotransmission ◽  
Hyperactivity Disorder ◽  
Incentive Value

Schizophrenia, Parkinson’s disease, and attention deficit hyperactivity disorder (ADHD) discusses how hyperactive dopaminergic neurotransmission appears to underlie schizophrenia’s positive symptoms, loss of dopaminergic neurons in adulthood leads to Parkinson’s disease, and dopamine neuron hypofunction in childhood and adolescence may underlie ADHD. Positive schizophrenia symptoms may arise from excessive incentive learning that is gradually lost with antipsychotic treatment. Declarative learning and memory may contribute to delusions based on excessive incentive learning. Loss of responsiveness to environmental stimuli in Parkinson’s may result from a decrease of their conditioned incentive value and inverse incentive learning. Conditioned incentive stimuli not encountered while in a state of decreased dopaminergic neurotransmission may retain their incentive value, producing apparent kinesia paradoxa. Dopamine hypofunction in juveniles does not lead to hypokinesia but may result in loss of incentive learning that focuses attention. Pro-dopaminergic drugs have a calming effect in ADHD, presumably because they reinstate normal incentive learning.

The use of dopamine agonists in newly diagnosed Parkinson's disease patients has changed

2014 ◽  
Vol 5 (5) ◽  
pp. 357-358
Author(s):  
H. Kuusisto ◽  
P. Hujanen ◽  
T. Mattila ◽  
T. Luukkaala ◽  
T. Keränen
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
Newly Diagnosed
Sign in / Sign up

Export Citation Format

Share Document